会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 2. 发明申请
    • Gpr41 and Modulators Thereof for the Treatment of Insulin-Related Disorders
    • Gpr41及其调节剂治疗胰岛素相关性疾病
    • US20080312277A1
    • 2008-12-18
    • US11666910
    • 2005-11-01
    • James N. LeonardZhi Liang ChuMarc A. BruceP. Douglas Boatman
    • James N. LeonardZhi Liang ChuMarc A. BruceP. Douglas Boatman
    • A61K31/47G01N33/566C07D215/38A61P3/10A61K31/4709C07D407/04
    • G01N33/66G01N2500/04
    • The present invention relates to a method for identifying a glycemic stabilizing compound by: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is modulated, where a modulation in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. In addition, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is increased, wherein an increase in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound. Further, the invention relates to a method for identifying a glycemic stabilizing compound, comprising: a) contacting a candidate compound with GPR41, and b) determining whether GPR41 functionality is decreased, wherein a decrease in GPR41 functionality is indicative of the candidate compound being a glycemic stabilizing compound.
    • 本发明涉及通过以下方式鉴定血糖稳定化合物的方法:a)使候选化合物与GPR41接触,和b)确定是否调节GPR41功能性,其中GPR41官能度的调节指示候选化合物是血糖稳定剂 复合。 此外,本发明涉及一种鉴定血糖稳定化合物的方法,包括:a)使候选化合物与GPR41接触,和b)确定GPR41的功能是否增加,其中GPR41功能的增加指示候选化合物为 血糖稳定化合物。 此外,本发明涉及用于鉴定血糖稳定化合物的方法,其包括:a)使候选化合物与GPR41接触,和b)确定GPR41的功能性是否降低,其中GPR41官能度的降低指示候选化合物为 血糖稳定化合物。
    • 6. 发明授权
    • Fused pyrazole derivatives and methods of treatment of metabolic-related disorders thereof
    • 融合的吡唑衍生物及其代谢相关病症的治疗方法
    • US07241792B2
    • 2007-07-10
    • US11315753
    • 2005-12-22
    • P. Douglas BoatmanThomas O. SchraderGraeme SemplePhilip J. SkinnerJae-Kyu Jung
    • P. Douglas BoatmanThomas O. SchraderGraeme SemplePhilip J. SkinnerJae-Kyu Jung
    • A61K31/407C07D231/54
    • C07D403/04C07D209/80C07D209/88C07D231/54C07D265/36C07D471/04C07D471/14
    • The present invention relates to certain fused pyrazole derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, which exhibit useful pharmacological properties, for example, as agonists for the RUP25 receptor. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of α-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, DP receptor antagonists, and the like.
    • 本发明涉及式(Ia)的某些稠合吡唑衍生物及其药学上可接受的盐,其表现出有用的药理学性质,例如作为RUP25受体的激动剂。 本发明还提供含有本发明化合物的药物组合物,以及使用本发明化合物和组合物治疗代谢相关疾病包括血脂异常,动脉粥样硬化,冠心病,胰岛素抵抗,2型糖尿病的方法 ,综合征-X等。 此外,本发明还提供本发明化合物与其它活性剂如属于α-葡糖苷酶抑制剂类,醛糖还原酶抑制剂,双胍类,HMG-CoA还原酶抑制剂,角鲨烯合成 抑制剂,贝特类,LDL分解代谢增强剂,血管紧张素转换酶(ACE)抑制剂,胰岛素分泌增强剂,DP受体拮抗剂等。